Titre:
  • Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Auteur:Millot, Frédéric; Suciu, Stefan; Philippe, N; Benoît, Yves; Mazingue, F; Uyttebroeck, A; Lutz, Pierre; Mechinaud, F; Robert, Alain; Boutard, Patrick; Marguerite, Geneviève; Ferster, Alina; Plouvier, Emmanuel; Rialland, X; Behard, C; Plantaz, D; Dresse, Marie-Françoise; Philippet, Pierre; Norton, Lucilia; Thyss, Antoine; Dastugue, N; Waterkeyn, C; Vilmer, E; Otten, Jacques; Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer,
Informations sur la publication:Journal of clinical oncology, 19, 7, page (1935-1942)
Statut de publication:Publié, 2001-04
Sujet CREF:Pédiatrie
Cancérologie
Hématologie
MeSH keywords:Vincristine -- administration & dosage
Note générale:Clinical Trial
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Langue:Anglais
Identificateurs:urn:issn:0732-183X
info:pmid/11283125